Antispasmodic action of 1-diethylaminoethyl-3-(p-methoxybenzyl)-2-quinoxalone (P 201-1) and its inhibitory effect on cyclic 3',5'-nucleotide phosphodiesterase (PDE) activity.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D002540:Cerebral Cortex / Q000201:enzymology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D007082:Ileum / Q000201:enzymology; D007700:Kinetics; D008099:Liver / Q000201:enzymology; D008274:Magnesium / Q000494:pharmacology; D008297:Male; D010208:Papaverine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors; D011810:Quinoxalines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats
D010276:Parasympatholytics; D010726:Phosphodiesterase Inhibitors; D011810:Quinoxalines; D010208:Papaverine; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D008274:Magnesium